Skip to main content

Contraceptive Technology Update

RSS  

Articles

  • CTU Updates

    New video reviews teen birth control options; NAMS issues revised menopause guidelines
  • Contraceptive shot offers family planning options

    Women in the West African nation of Burkina Faso now have access to a lower-dose formulation of depot medroxyprogesterone acetate (DMPA) packaged in a novel injection system that is designed to increase access to contraception at all levels of the health system.
  • Short-term bleeding and cramping with LARC method satisfaction eyed

    Research findings from the Contraceptive CHOICE Project, a St. Louis prospective cohort study, examined the short-term bleeding and cramping patterns of long-acting reversible contraception (LARC) methods and the impact on method satisfaction.
  • Pay for performance may impact family planning

    The North American Menopause Society and the International Society for the Study of Women’s Sexual Health have developed and endorsed the term “genitourinary syndrome of menopause” (GSM) to define “a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra and bladder.”
  • New terminology helps menopausal talks

    Research findings indicate that brief telephone counseling sustained long-term impact from a sexually transmitted infections/HIV intervention program among African American female adolescents.
  • Are women getting their desired LARC methods?

    Women in Texas face hurdles when it comes to getting long-acting reversible contraceptive (LARC) methods following cuts to the state family planning budget by the 2011 Texas State Legislature.
  • What are the top myths about pills?

    Your next patient tells you she would like to use oral contraceptives (OCs) for birth control, but she says a family member told her using pills would affect her long-term fertility. What information do you provide her regarding OCs?
  • Tenofovir gel makes strides in development

    Microbicide research is moving forward with two new developments: the Food and Drug Administration (FDA) has granted Fast Track approval designation for 1% tenofovir gel, which will facilitate the development and expedite the review of the drug.
  • More data emerge from Women's Health Initiative

    Results from a long-term follow-up analysis of participants in the Women's Health Initiative (WHI) suggest that among postmenopausal women, use of estrogen plus progestin is associated with an increased incidence of breast cancers that are more advanced, and with a higher risk of deaths attributable to breast cancer.
  • Ask The Experts: What's the evidence for using two condoms?

    Question: What is the evidence that two condoms may be used at once? Who does this? What are their reasons for doing this? What are the other things that can do done to prevent condom breakage?